EAU 2013 - Programme Book - YouMed

Saturday, 16 March
Sponsored Session
18.00 - 19.30 Increasing evidence of effectiveness of GAG therapy in different forms
of cystitis
Amber Hall 1-2 - Level S2
Symposium
Chair: P.F. Bassi, Rome (IT)
The scenario of bladder dysfunctions: Insights into the therapeutic potential of GAG therapy
P.F. Bassi, Rome (IT)
Management of interstitial cystitis/bladder pain syndrome with GAGs
M. Cervigni, Rome (IT)
Efficacy of GAGS treatment in chemical and radiation cystitis
E. Finazzi Agro, Rome (IT)
Management of recurrent urinary tract infections with IALURIL®
R. Damiano, Catanzaro (IT)
Clinical experience with IALURIL®: Results of a multicentric survey
R. Tomaskin, Martin (SK)
Final remarks
P.F. Bassi, Rome (IT)
Discussion
Aims and objectives
Glycosaminoglycan (GAG) therapy is now being studied for the treatment of a wide variety of acquired and
inherited diseases in different therapeutic areas, including bladder disorders such as urinary tract infections,
painful bladder syndrome/interstitial cystitis, cystitis following radiation therapy or chemical agents.
The positive outcomes obtained with a combination of hyaluronic acid and chondroitin sulphate administered
intravesically in patients with an history of bladder damage, with the aim of restoring the integrity of the
glycosaminoglycan layer of the urothelium, suggest that such therapeutic approach might be beneficial. A
faculty of experts will review the results of the recent clinical investigations with this GAG combination and
discuss its therapeutic applications.
Sponsored by IBSA INSTITUT BIOCHIMIQUE
EAU Milan 2013
405
Sponsored Sessions